Home The Word Brain	My Amedeo FAQ Privacy About
	CC Journal Club Our weekly journal club for junior residents and medical students

Lung Cancer

Free Subscription Articles published in J Thorac Oncol Retrieve available abstracts of 307 articles: HTML format

Single Articles

April 2025
1. BOERI M, Zanghi A, Pastorino U
   New Horizons in Lung Cancer Screening: Eligibility Criteria, Risk Models, and Emerging Challenges.
   J Thorac Oncol. 2025;20:422-424.
   PubMed    
   
   
   
2. KIM YW, Lee CT
   Advancing the Implementation of Risk Model-Based Lung Cancer Screening.
   J Thorac Oncol. 2025;20:419-421.
   PubMed    
   
   
   
3. PARIKH K, Hashmi A, Chauhan PS, Chaudhuri AA, et al
   Plasma-First Testing in Advanced Lung Cancer: Evidence and Implications.
   J Thorac Oncol. 2025;20:411-414.
   PubMed    
   
   
   
4. XIA Y, Wang K, Zhao J, Arter Z, et al
   Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
   J Thorac Oncol. 2025;20:465-474.
   PubMed     Abstract available
   
   
   
5. NAKAGAWA K, Garon EB, Seto T, Nishio M, et al
   RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
   J Thorac Oncol. 2025;20:487-499.
   PubMed     Abstract available
   
   
   
6. BLECHTER B, Hsiung CA, Wang X, Zhang H, et al
   Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.
   J Thorac Oncol. 2025;20:521-530.
   PubMed     Abstract available
   
   
   
7. LEUNISSEN DJG, Moonen L, von der Thusen JH, den Bakker MA, et al
   Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids.
   J Thorac Oncol. 2025;20:451-464.
   PubMed     Abstract available
   
   
   March 2025
8. SEDER CW, Chang SC, Towe CW, Puri V, et al
   Anatomic Lung Resection is Associated with Improved Survival Compared with Wedge Resection for Stage IA (
   J Thorac Oncol. 2025 Mar 23:S1556-0864(25)00641.
   PubMed     Abstract available
   
   
   
9. HAKOZAKI T, Tanaka K, Shiraishi Y, Sekino Y, et al
   Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON).
   J Thorac Oncol. 2025 Mar 7:S1556-0864(25)00106.
   PubMed     Abstract available
   
   
   
10. CHEN P, Wang H, Tang Z, Shi J, et al
    Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells.
    J Thorac Oncol. 2025 Mar 6:S1556-0864(25)00109.
    PubMed     Abstract available
    
    
    
11. BROWN M, Myers R, Lam S
    Enlarging the Reach of Screening and Early Detection of Lung Cancer.
    J Thorac Oncol. 2025;20:249-251.
    PubMed    
    
    
    
12. CHOU TY, Dacic S, Wistuba I, Beasley MB, et al
    Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2025;20:311-330.
    PubMed     Abstract available
    
    
    
13. LU S, Wu L, Wang Q, Wang Z, et al
    Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
    J Thorac Oncol. 2025;20:366-382.
    PubMed     Abstract available
    
    
    
14. MARINELLI D, Nuccio A, Di Federico A, Ambrosi F, et al
    Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.
    J Thorac Oncol. 2025;20:285-295.
    PubMed     Abstract available
    
    
    February 2025
15. XIE D, Zhang L, He N, Yang C, et al
    Overdiagnosis of Lung Cancer due to Introduction of Low-Dose Computed Tomography in Average-Risk Populations in China.
    J Thorac Oncol. 2025 Feb 13:S1556-0864(25)00072.
    PubMed     Abstract available
    
    
    
16. CALLES A, Navarro A, Doger Speville Uribe BG, Alvarez Colome E, et al
    Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study.
    J Thorac Oncol. 2025 Feb 10:S1556-0864(25)00064.
    PubMed     Abstract available
    
    
    
17. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
    Corrigendum to 'The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer' [Journal of Thoraci
    J Thorac Oncol. 2025 Feb 9:S1556-0864(25)00050.
    PubMed    
    
    
    
18. HAN B, Liu J, Wu L, Zhao Y, et al
    Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00062.
    PubMed     Abstract available
    
    
    
19. LI YS, Yu Q, Bu Q, Lin L, et al
    First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial.
    J Thorac Oncol. 2025 Feb 8:S1556-0864(25)00063.
    PubMed     Abstract available
    
    
    
20. ABBAR B, Labreche K, Cadranel J, Veyri M, et al
    HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Feb 7:S1556-0864(25)00060.
    PubMed     Abstract available
    
    
    
21. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Failure to Include Nonsmokers in Computed Tomography Screening for Lung Cancer is Unjust".
    J Thorac Oncol. 2025;20:e39-e40.
    PubMed    
    
    
    
22. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges".
    J Thorac Oncol. 2025;20:e36-e37.
    PubMed    
    
    
    
23. LI J, Zhang Y, Fu T, Tong Y, et al
    Lung Cancer Screening in Low-Risk Populations: Ethical Considerations, Technological Advancements, and Socioeconomic Challenges.
    J Thorac Oncol. 2025;20:e35-e36.
    PubMed    
    
    
    
24. SILVESTRI GA, Young R, Tanner NT, Mazzone P, et al
    A Response to the Letter to the Editor: "Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening".
    J Thorac Oncol. 2025;20:e34.
    PubMed    
    
    
    
25. CUI Y
    Secondhand Smoke in Low-Risk Groups: A Hidden Danger in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e33-e34.
    PubMed    
    
    
    
26. RIZZO MM, Barros M, Chimondeguy D, Dalurzo ML, et al
    Lung Cancer in Argentina.
    J Thorac Oncol. 2025;20:144-149.
    PubMed    
    
    
    
27. BAK M, Park H, Lee SH, Lee N, et al
    The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population.
    J Thorac Oncol. 2025;20:167-176.
    PubMed     Abstract available
    
    
    
28. NAKAGAWA K, Watanabe SI, Wakabayashi M, Yotsukura M, et al
    Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.
    J Thorac Oncol. 2025;20:157-166.
    PubMed     Abstract available
    
    
    
29. LEE J, Jeon JH, Chung JH, Son JW, et al
    Prognostic Impact of Non-Predominant Lepidic Components in Pathologic Stage I Invasive Nonmucinous Adenocarcinoma.
    J Thorac Oncol. 2025;20:194-202.
    PubMed     Abstract available
    
    
    January 2025
30. LIAO W, Ray MA, Patel A, Roma J, et al
    Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Program.
    J Thorac Oncol. 2025 Jan 30:S1556-0864(25)00057.
    PubMed     Abstract available
    
    
    
31. BOSTOCK IC, Fox AH, Ward RC, Engelhardt KE, et al
    Outcomes After Surgical Management of Early-Stage Lung Cancer in Octogenarians: An in-depth Analysis of a Nationally Representative Cohort.
    J Thorac Oncol. 2025 Jan 28:S1556-0864(25)00053.
    PubMed     Abstract available
    
    
    
32. TAMMEMAGI MC, Borondy-Kitts A, Field JK, Henschke CI, et al
    Lung cancer screening program quality indicators - review & recommendations - An International Association for the Study of Lung Cancer Delphi process study.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00052.
    PubMed     Abstract available
    
    
    
33. GANDHI MM, Elkrief A, Moore CG, Ricciuti B, et al
    Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with outcomes to immunotherapy +/- chemotherapy in nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00049.
    PubMed     Abstract available
    
    
    
34. TSAO MS, Rosenthal A, Nicholson AG, Detterbeck F, et al
    The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2025 Jan 24:S1556-0864(25)00046.
    PubMed     Abstract available
    
    
    
35. AKAMATSU H, Sakata S, Azuma K, Yoshioka H, et al
    A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET).
    J Thorac Oncol. 2025 Jan 17:S1556-0864(25)00007.
    PubMed     Abstract available
    
    
    
36. GENDARME S, Irajizad E, Long JP, Fahrmann JF, et al
    Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials.
    J Thorac Oncol. 2025 Jan 9:S1556-0864(25)00004.
    PubMed     Abstract available
    
    
    
37. BESSE B, Goto K, Wang Y, Lee SH, et al
    Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550.
    PubMed     Abstract available
    
    
    
38. FUKUI T, Mamesaya N, Takahashi T, Kishi K, et al
    A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548.
    PubMed     Abstract available
    
    
    
39. DOWLATI A, Chiang AC, Cervantes A, Babu S, et al
    Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
    J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02549.
    PubMed     Abstract available
    
    
    
40. HUBER RM, Lam S, Cavic M, Balata H, et al
    Response to the Letters to the Editor by Jing Peng and Colleagues and by Lauren C Leiman Regarding the Manuscript "Terminology Issues in Screening and Early Detection of Lung Cancer-International Association for the Study of Lung Cancer Early Detectio
    J Thorac Oncol. 2025;20:e6-e8.
    PubMed    
    
    
    
41. PENG J, Zhao L, Shan D
    Enhancing Clinical Precision and Patient Communication in Lung Cancer Screening.
    J Thorac Oncol. 2025;20:e3-e4.
    PubMed    
    
    
    
42. GADGEEL SM, Jensen E, Shamoun M, Rajagopalan K, et al
    Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy and Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025;20:e11-e12.
    PubMed    
    
    
    
43. BORGHAEI H, Mok T
    Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met.
    J Thorac Oncol. 2025;20:17-19.
    PubMed    
    
    
    
44. LI HJ, Qiu ZB, Wang MM, Zhang C, et al
    Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma.
    J Thorac Oncol. 2025;20:52-64.
    PubMed     Abstract available
    
    
    
45. PETERS S, Cho BC, Luft AV, Alatorre-Alexander J, et al
    Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
    J Thorac Oncol. 2025;20:76-93.
    PubMed     Abstract available
    
    
    December 2024
46. WARKENTIN MT, Tammemagi MC, Vakil E, Bedard ELR, et al
    Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening.
    J Thorac Oncol. 2024 Dec 30:S1556-0864(24)02546.
    PubMed     Abstract available
    
    
    
47. LEE JB, Choi SJ, Shim HS, Park BJ, et al
    Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).
    J Thorac Oncol. 2024 Dec 26:S1556-0864(24)02544.
    PubMed     Abstract available
    
    
    
48. GABE R, Crosbie PAJ, Vulkan D, Bailey H, et al
    Prospective evaluation of lung cancer screening eligibility criteria and lung cancer detection in the Yorkshire Lung Screening Trial.
    J Thorac Oncol. 2024 Dec 19:S1556-0864(24)02535.
    PubMed     Abstract available
    
    
    
49. PASSIGLIA F, Listi A, Bironzo P, Merlini A, et al
    Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA).
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529.
    PubMed     Abstract available
    
    
    
50. SWALDUZ A, Schiffler C, Curcio H, Ambasager B, et al
    LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02530.
    PubMed     Abstract available
    
    
    
51. TAVERNARI D, Borgeaud M, Liu X, Kaushal P, et al
    Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02531.
    PubMed     Abstract available
    
    
    
52. HOFFMANN H, Nicholson AG, Detterbeck FC, Tsao MS, et al
    The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surge
    J Thorac Oncol. 2024 Dec 13:S1556-0864(24)02526.
    PubMed     Abstract available
    
    
    
53. KIM SY, Silvestri GA, Kim YW, Kim RY, et al
    Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Study.
    J Thorac Oncol. 2024 Dec 9:S1556-0864(24)02503.
    PubMed     Abstract available
    
    
    
54. PHILLIPS WJ, Watson AS, Camidge DR
    The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.
    J Thorac Oncol. 2024 Dec 4:S1556-0864(24)02498.
    PubMed     Abstract available
    
    
    
55. XU X, Xie J, Luo Z
    Strengthening the Evidence: Expanding Research on Passive Smoking and Lung Cancer.
    J Thorac Oncol. 2024;19:e94-e95.
    PubMed    
    
    
    
56. LI Z, Liu J, Liu H, Wu C, et al
    Comment on "A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology".
    J Thorac Oncol. 2024;19:e89-e90.
    PubMed    
    
    
    
57. ZHOU RX, Ye DW
    Reply to the Letter to the Editor: The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
    J Thorac Oncol. 2024;19:e82-e84.
    PubMed    
    
    
    
58. WANG L, Wang Z, Wang G
    The Relationship Between Air Pollution and Lung Cancer: Differences in Sensitivity Across Regions and Populations.
    J Thorac Oncol. 2024;19:e81-e82.
    PubMed    
    
    
    
59. JENSEN SO, Moore DA, Surani AA, Crosbie PAJ, et al
    Second Primary Lung Cancer-Potential Areas of Ambiguity.
    J Thorac Oncol. 2024;19:e101-e102.
    PubMed    
    
    
    
60. NIU Y, Xie J, Li Z
    Second Primary Lung Cancer-Potential Areas of Ambiguity.
    J Thorac Oncol. 2024;19:e100-e101.
    PubMed    
    
    
    
61. GUISSEVE A, Mualinque A, Cossa M, Jerez AD, et al
    Lung Cancer in Mozambique.
    J Thorac Oncol. 2024;19:1599-1605.
    PubMed    
    
    
    
62. TONG BC, Stinchcombe TE
    Lung Cancer Screening and Early Detection Terminology: Time to Sing From the Same Song Sheet.
    J Thorac Oncol. 2024;19:1589-1590.
    PubMed    
    
    
    
63. KOZONO D, Hua X, Wu MC, Tolba KA, et al
    Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
    J Thorac Oncol. 2024;19:1618-1629.
    PubMed     Abstract available
    
    
    November 2024
64. HEERSCHE N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, et al
    Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer.
    J Thorac Oncol. 2024 Nov 29:S1556-0864(24)02488.
    PubMed     Abstract available
    
    
    
65. KAZI A, Kantilal Vasiyani HK, Ghosh D, Bandyopadhyay D, et al
    FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.
    J Thorac Oncol. 2024 Nov 25:S1556-0864(24)02485.
    PubMed     Abstract available
    
    
    
66. IGNATIUS OU SH, Solomon BJ, Besse B, Bearz A, et al
    Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study.
    J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02484.
    PubMed     Abstract available
    
    
    
67. DAMARAJU V, Krushna Karri JK, Gandrakota G, Marimuthu Y, et al
    Low dose computed tomography for lung cancer screening in Tuberculosis endemic countries: A Systematic Review and Meta-analysis.
    J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02483.
    PubMed     Abstract available
    
    
    
68. LEVY A, Rusthoven CG, Brown PD, Le Pechoux C, et al
    PCI for Patients with Small Cell Lung Cancer: A New Perspective in the Immunotherapy Era.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02446.
    PubMed     Abstract available
    
    
    
69. ZHAO S, Zhou H, Yang N, Wang Z, et al
    Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.
    J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445.
    PubMed     Abstract available
    
    
    
70. TUMINELLO S, Flores R, Untalan M, Ivic-Pavlicic T, et al
    Predicted effect of incidental pulmonary nodule findings on Non-Small Cell Lung Cancer mortality.
    J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02444.
    PubMed     Abstract available
    
    
    
71. ECHEPARE M, Picabea B, Arricibita A, Teijeira A, et al
    DSTYK Inhibition Sensitizes Non-Small Cell Lung Cancer To Taxane-Based Chemotherapy.
    J Thorac Oncol. 2024 Nov 11:S1556-0864(24)02438.
    PubMed     Abstract available
    
    
    
72. GRAY JE, Schenker M, Nahit Sendur MA, Leonova V, et al
    The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2024 Nov 7:S1556-0864(24)02435.
    PubMed     Abstract available
    
    
    
73. KARIM NA, Miao J, Reckamp KL, Gay CM, et al
    Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer. S1929.
    J Thorac Oncol. 2024 Nov 4:S1556-0864(24)02431.
    PubMed     Abstract available
    
    
    
74. OLTEANU GE, Vigdorovits A, Barna RA, Mazilu L, et al
    Lung Cancer in Romania.
    J Thorac Oncol. 2024;19:1492-1503.
    PubMed    
    
    
    
75. D'AMOURS MF, Hughesman CB, Yip ST, Ho C, et al
    The Game is Afoot - Seeking Early-Stage Lung Cancer Circulating Tumor DNA.
    J Thorac Oncol. 2024;19:1479-1481.
    PubMed    
    
    
    
76. ADJEI AA
    How Can We Conquer Lung Cancer?
    J Thorac Oncol. 2024;19:1477-1478.
    PubMed    
    
    
    
77. KINDLER HL, Rosenthal A, Giroux DJ, Nowak AK, et al
    The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
    J Thorac Oncol. 2024;19:1564-1577.
    PubMed     Abstract available
    
    
    
78. PARIKH K, Dimou A, Leventakos K, Mansfield AS, et al
    Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.
    J Thorac Oncol. 2024;19:1539-1549.
    PubMed     Abstract available
    
    
    
79. HONG TH, Hwang S, Dasgupta A, Abbosh C, et al
    Clinical Utility of Tumor-Naive Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.
    J Thorac Oncol. 2024;19:1512-1524.
    PubMed     Abstract available
    
    
    October 2024
80. HOCHMAIR M, Schenker M, Dols MC, Kim TM, et al
    Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.
    J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420.
    PubMed     Abstract available
    
    
    
81. CHEN Z, Wu L, Wang Q, Yu Y, et al
    Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial.
    J Thorac Oncol. 2024 Oct 26:S1556-0864(24)02421.
    PubMed     Abstract available
    
    
    
82. UMEMURA S, Udagawa H, Ikeda T, Murakami H, et al
    Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib.
    J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02378.
    PubMed     Abstract available
    
    
    
83. PETERS S, Paz-Ares LG, Reck M, Carbone DP, et al
    Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
    J Thorac Oncol. 2024 Oct 4:S1556-0864(24)02355.
    PubMed     Abstract available
    
    
    
84. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
    A Response to the Letter to the Editor: "Comment on Stereotactic Body Radiotherapy for Centrally Located Inoperable Early Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
    J Thorac Oncol. 2024;19:e57-e59.
    PubMed    
    
    
    
85. XU Z, Jiang J, Guo H, Zhao D, et al
    Comment on "Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results".
    J Thorac Oncol. 2024;19:e56-e57.
    PubMed    
    
    
    
86. RAMI-PORTA R, Call S, Sanz-Santos J
    Reply to "Impact of the Ninth IASLC TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging" by Faria et al.
    J Thorac Oncol. 2024;19:e55-e56.
    PubMed    
    
    
    
87. FARIA N, Costa MI, Lacerda C, Sucena M, et al
    Impact of the Ninth International Association for the Study of Lung Cancer TNM Classification on Endobronchial Ultrasound for Lung Cancer Staging.
    J Thorac Oncol. 2024;19:e53-e55.
    PubMed    
    
    
    
88. KOHNO T, Mochizuki A
    Response to Letter to the Editor.
    J Thorac Oncol. 2024;19:e52-e53.
    PubMed    
    
    
    
89. GU X, Han Z, Shi W
    Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis".
    J Thorac Oncol. 2024;19:e51-e52.
    PubMed    
    
    
    
90. ZHUANG WT, Hu LY, Fang WF
    Response to Commentary on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    J Thorac Oncol. 2024;19:e50-e51.
    PubMed    
    
    
    
91. PAN Y
    Comment on "EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47".
    J Thorac Oncol. 2024;19:e49-e50.
    PubMed    
    
    
    
92. SHI Y
    A Response to the Letter to the Editor: Response to Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
    J Thorac Oncol. 2024;19:e48.
    PubMed    
    
    
    
93. GE MW, Chen HL
    Ficonalkib's Promise and the Path Forward: A Comment on Advanced ALK-Positive NSCLC Treatment.
    J Thorac Oncol. 2024;19:e47-e48.
    PubMed    
    
    
    
94. CABALLE-PEREZ E, Cabrera-Miranda L, Arrieta O
    Exploring EGFR Mutations in Resected Stage I-III NSCLC in Low- and Middle-Income Countries: Bridging the Gap in Global Cancer Care.
    J Thorac Oncol. 2024;19:1367-1369.
    PubMed    
    
    
    
95. PUJOL JL, Erich Eberhardt WE
    Familial Lung Cancers Caused by EGFR Germline Mutations: The Frequency Is Probably Underestimated but Specific Genotypic Features and Some Particular Disease Characteristics Should Help Their Screening.
    J Thorac Oncol. 2024;19:1364-1366.
    PubMed    
    
    
    
96. SOO RA, Reungwetwattana T, Perroud HA, Batra U, et al
    Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study.
    J Thorac Oncol. 2024;19:1449-1459.
    PubMed     Abstract available
    
    
    
97. PAN K, Owens J, Elamin Y, Lu C, et al
    Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations.
    J Thorac Oncol. 2024;19:1438-1448.
    PubMed     Abstract available
    
    
    
98. BUROTTO M, Zvirbule Z, Alvarez R, Chewaskulyong B, et al
    Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
    J Thorac Oncol. 2024;19:1460-1466.
    PubMed     Abstract available
    
    
    September 2024
99. SAID BI, Geng Y, Badiyan SN, Bang A, et al
    Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee.
    J Thorac Oncol. 2024 Sep 28:S1556-0864(24)02353.
    PubMed     Abstract available
    
    
    
100. PARK HS, Rimner A, Amini A, Chang JY, et al
     Executive Summary of the American Radium Society(R) (ARS) Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Systematic Review and Guidelines.
     J Thorac Oncol. 2024 Sep 11:S1556-0864(24)02268.
     PubMed     Abstract available
     
     
     
101. NASSAR AH, Jayakrishnan R, Feng J, Shepherd F, et al
     Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
     J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265.
     PubMed     Abstract available
     
     
     
102. CHEN H, Yang S, Wang L, Wu Y, et al
     High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A prospective real-world study.
     J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02269.
     PubMed     Abstract available
     
     
     
103. HORNE A, Harada K, Brown KD, Lee Min Chua K, et al
     Erratum to "Treatment response biomarkers: working towards personalised radiotherapy for lung cancer. [Journal of Thoracic Oncology Vol. 19 No. 8: 1164-1185]".
     J Thorac Oncol. 2024 Sep 5:S1556-0864(24)00775.
     PubMed    
     
     
     
104. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
     A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e44-e45.
     PubMed    
     
     
     
105. JIANG Y, Zhang L
     Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e43.
     PubMed    
     
     
     
106. LEVY A, Adebahr S, Hurkmans C, Fortpied C, et al
     A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy.
     J Thorac Oncol. 2024;19:e41-e43.
     PubMed    
     
     
     
107. ROMA L, Bubendorf L
     Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
     J Thorac Oncol. 2024;19:e38-e39.
     PubMed    
     
     
     
108. ZHOU L, Li M, Li W
     Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma.
     J Thorac Oncol. 2024;19:e37-e38.
     PubMed    
     
     
     
109. TUMINELLO S, Gulati S, Ivic-Pavlicic T, Flores R, et al
     Response to: "The Value of Incidental Imaging for Early Stage Lung Cancer in High-Risk Nonscreening Cohort: Some Additional Considerations?".
     J Thorac Oncol. 2024;19:e36.
     PubMed    
     
     
     
110. NIU Y, Xie J, Li Z
     The Value of Incidental Imaging for Early-Stage Lung Cancer in a High-Risk Non-Screening Cohort: Some Additional Considerations?
     J Thorac Oncol. 2024;19:e34-e35.
     PubMed    
     
     
     
111. HIGASHIYAMA RI, Yoshida T
     A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
     J Thorac Oncol. 2024;19:e33-e34.
     PubMed    
     
     
     
112. HAN Z, Liu L, Jiang Y
     Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.
     J Thorac Oncol. 2024;19:e31-e32.
     PubMed    
     
     
     
113. ANDERSEN H, Aro M, Kaarteenaho R, Koivunen J, et al
     Lung Cancer in Finland.
     J Thorac Oncol. 2024;19:1265-1271.
     PubMed    
     
     
     
114. YANG CY, Lee MR, Yang PC
     Beyond Low-Dose Computed Tomography: Emerging Diagnostic Tools for Early Lung Cancer Detection.
     J Thorac Oncol. 2024;19:1261-1264.
     PubMed    
     
     
     
115. ROSSI S, Costa R, di Federico A, Lo Bianco F, et al
     Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report.
     J Thorac Oncol. 2024;19:1352-1355.
     PubMed     Abstract available
     
     
     
116. LEVY A, Adebahr S, Hurkmans C, Ahmed M, et al
     Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.
     J Thorac Oncol. 2024;19:1297-1309.
     PubMed     Abstract available
     
     
     
117. ROMA L, Ercan C, Conticelli F, Akyurek N, et al
     Tracing Tumor Heterogeneity of Pleomorphic Carcinoma of the Lung.
     J Thorac Oncol. 2024;19:1284-1296.
     PubMed     Abstract available
     
     
     
118. GILL RR, Nowak AK, Giroux DJ, Eisele M, et al
     The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
     J Thorac Oncol. 2024;19:1310-1325.
     PubMed     Abstract available
     
     
     August 2024
119. ZHOU Q, Meng X, Sun L, Huang D, et al
     Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study.
     J Thorac Oncol. 2024 Aug 8:S1556-0864(24)00762.
     PubMed     Abstract available
     
     
     
120. HUBER RM, Cavic M, Balata H, Kitts AB, et al
     From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations.
     J Thorac Oncol. 2024 Aug 2:S1556-0864(24)00747.
     PubMed     Abstract available
     
     
     
121. ERNST SM, von der Thusen JH, Dubbink HJ, Dingemans AC, et al
     Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e29-e30.
     PubMed    
     
     
     
122. KOSAKA N, Kataoka Y
     Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib".
     J Thorac Oncol. 2024;19:e28.
     PubMed    
     
     
     
123. CAMERON RB, Hines JB, Torri V, Garassino MC, et al
     A Response Letter by Cameron et al.
     J Thorac Oncol. 2024;19:e26-e28.
     PubMed    
     
     
     
124. HUANG J, Osarogiagbon RU
     Author's Reply.
     J Thorac Oncol. 2024;19:e24.
     PubMed    
     
     
     
125. PONVILAWAN B, Subramanian J, Bansal D
     The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC.
     J Thorac Oncol. 2024;19:e24-e26.
     PubMed    
     
     
     
126. TRISOLINI R
     The Devil Is in the Details: A Hidden Obstacle to Implementing the Proposed Revision of the N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2024;19:e23.
     PubMed    
     
     
     
127. KUBO N
     Response to Letter to the Editor.
     J Thorac Oncol. 2024;19:e22.
     PubMed    
     
     
     
128. SHI L, Bao Z
     Accurate Prognostic Factor for Carbon-Ion Radiotherapy in Operable Stage I NSCLC.
     J Thorac Oncol. 2024;19:e21-e22.
     PubMed    
     
     
     
129. SILVESTRI GA, Young RP, Tanner NT, Mazzone P, et al
     Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not.
     J Thorac Oncol. 2024;19:1155-1163.
     PubMed     Abstract available
     
     
     
130. MAKAREM M, Janne PA
     "Tumor-Free Survival" Outweighs the Side Effects of Combined Anti-EGF Therapy and Chemotherapy in Patients With NSCLC.
     J Thorac Oncol. 2024;19:1151-1154.
     PubMed    
     
     
     
131. ZHENG MM, Wu YL
     "Tumor-free survival" Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC.
     J Thorac Oncol. 2024;19:1146-1150.
     PubMed    
     
     
     
132. LAISAAR T, Innos K, Jaal J, Oselin K, et al
     Lung Cancer in Estonia.
     J Thorac Oncol. 2024;19:1138-1145.
     PubMed    
     
     
     
133. WOODARD GA, Jablons DM
     Shades of Gray: Do Never Smokers Benefit From Lung Cancer Screening Programs?
     J Thorac Oncol. 2024;19:1135-1137.
     PubMed    
     
     
     
134. TURK MA
     Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
     J Thorac Oncol. 2024;19:1133-1134.
     PubMed    
     
     
     
135. PERRONE F, Leonetti A, Tiseo M, Facchinetti F, et al
     Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in "PD-L1 Negative" NSCLC.
     J Thorac Oncol. 2024;19:1128-1132.
     PubMed    
     
     
     
136. GRAY SG, Mutti L, Meirson T
     Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer.
     J Thorac Oncol. 2024;19:1125-1127.
     PubMed    
     
     
     
137. HU LY, Zhuang WT, Chen MJ, Liao J, et al
     EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
     J Thorac Oncol. 2024;19:1186-1200.
     PubMed     Abstract available
     
     
     
138. WOLF AS, Eisele M, Giroux DJ, Gill R, et al
     The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.
     J Thorac Oncol. 2024;19:1242-1252.
     PubMed     Abstract available
     
     
     July 2024
139. VAN ROSSUM PSN, Wolfhagen N, van Bockel LW, Coremans IEM, et al
     Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
     J Thorac Oncol. 2024 Jul 25:S1556-0864(24)00684.
     PubMed     Abstract available
     
     
     
140. JENSEN SO, Moore DA, Surani AA, Crosbie PA, et al
     Second Primary Lung Cancer - an emerging issue in lung cancer survivors.
     J Thorac Oncol. 2024 Jul 24:S1556-0864(24)00683.
     PubMed     Abstract available
     
     
     
141. GRAY JE, Markovets A, Reungwetwattana T, Majem M, et al
     Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.
     J Thorac Oncol. 2024 Jul 17:S1556-0864(24)00676.
     PubMed     Abstract available
     
     
     
142. JUN S, Shukla NA, Durm G, Hui AB, et al
     Analysis of Circulating Tumor DNA Predicts Outcomes of Short Course Consolidation Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
     J Thorac Oncol. 2024 Jul 4:S1556-0864(24)00664.
     PubMed     Abstract available
     
     
     
143. LIN YL, Wang GS, Wei JC
     Rheumatoid Arthritis and Risk of Lung Cancer.
     J Thorac Oncol. 2024;19:e15-e16.
     PubMed    
     
     
     
144. YANG JJ, Wen W, Zheng W, Shu XO, et al
     "Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia".
     J Thorac Oncol. 2024;19:e14-e15.
     PubMed    
     
     
     
145. SHEN LT, Chen HL
     Some Thoughts on Lung Cancer Risk Prediction Models for Long-Term Smokers in Asia.
     J Thorac Oncol. 2024;19:e13-e14.
     PubMed    
     
     
     
146. AFRIYIE-MENSAH JS, Dadzie MA, Vanderpuye VDNK, Calys-Tagoe B, et al
     Lung Cancer in Ghana.
     J Thorac Oncol. 2024;19:966-972.
     PubMed    
     
     
     
147. MOCHIZUKI A, Shiraishi K, Honda T, Higashiyama RI, et al
     Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis.
     J Thorac Oncol. 2024;19:984-994.
     PubMed     Abstract available
     
     
     June 2024
148. SPICER JD, Cascone T, Wynes MW, Ahn MJ, et al
     Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).
     J Thorac Oncol. 2024 Jun 18:S1556-0864(24)00627.
     PubMed     Abstract available
     
     
     
149. HSU CK, Lai CC
     Association Between Rheumatoid Arthritis and the Risk of Lung Cancer.
     J Thorac Oncol. 2024;19:e9.
     PubMed    
     
     
     
150. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
     Finding One Treatment for All Advanced EGFR-positive NSCLC-An Infinite Task.
     J Thorac Oncol. 2024;19:e11-e12.
     PubMed    
     
     
     
151. CHO MH, Cho JH, Shin DW
     In Response.
     J Thorac Oncol. 2024;19:e10.
     PubMed    
     
     
     
152. RICCIUTI B, Garassino MC
     Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC.
     J Thorac Oncol. 2024;19:877-882.
     PubMed    
     
     
     
153. DICKHOFF C, Heineman DJ, van Dorp M, Senan S, et al
     The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard.
     J Thorac Oncol. 2024;19:862-865.
     PubMed    
     
     
     
154. UGALDE FIGUEROA P, Lacroix V, Van Schil PE
     Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint.
     J Thorac Oncol. 2024;19:858-861.
     PubMed    
     
     
     
155. LI MS, Ou SI
     Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come.
     J Thorac Oncol. 2024;19:855-857.
     PubMed    
     
     
     
156. PECCATORI FA, Florez N, Imbimbo M
     From Approximation to Precision: Fertility and Pregnancy Questions in Young Patients With Lung Cancer.
     J Thorac Oncol. 2024;19:852-854.
     PubMed    
     
     
     May 2024
157. ROCCO G, Pennazza G, Tan KS, Vanstraelen S, et al
     A real-world assessment of stage I lung cancer through electronic nose technology.
     J Thorac Oncol. 2024 May 16:S1556-0864(24)00211.
     PubMed     Abstract available
     
     
     
158. BILLE A, Ripley RT, Giroux DJ, Gill RR, et al
     The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma.
     J Thorac Oncol. 2024 May 9:S1556-0864(24)00208.
     PubMed     Abstract available
     
     
     
159. NOWAK AK, Giroux DJ, Eisele M, Rosenthal A, et al
     The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma.
     J Thorac Oncol. 2024 May 9:S1556-0864(24)00207.
     PubMed     Abstract available
     
     
     
160. NASSAR AH, Kim SY, Adib E, Naqash AR, et al
     Response letter by Nassar et al.
     J Thorac Oncol. 2024;19:e7-e8.
     PubMed    
     
     
     
161. CHEN CY, Wang GS, Wei JC
     Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
     J Thorac Oncol. 2024;19:e6-e7.
     PubMed    
     
     
     
162. ZHAO B, Yao L, Ma W
     Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
     J Thorac Oncol. 2024;19:e5-e6.
     PubMed    
     
     
     
163. SRINIVASALU VK, Patnaik RS, Kiong LS, Justin JS, et al
     Lung Cancer in Brunei Darussalam.
     J Thorac Oncol. 2024;19:698-705.
     PubMed    
     
     
     
164. LI Y, Adusumilli PS, Chou TY, Kadota K, et al
     Pro: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
     J Thorac Oncol. 2024;19:677-697.
     PubMed     Abstract available
     
     
     
165. BLAAUWGEERS H, Dickhoff C, Pelosi G, Timens W, et al
     Con: "Is Spread Through Air Spaces an In Vivo Phenomenon or an Inducible Artifact?".
     J Thorac Oncol. 2024;19:671-676.
     PubMed    
     
     
     
166. SHIH JY
     ERBB2 Amplification in NSCLC: How Many Faces?
     J Thorac Oncol. 2024;19:668-670.
     PubMed    
     
     
     
167. ISHIKAWA S
     Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision.
     J Thorac Oncol. 2024;19:666-667.
     PubMed    
     
     
     
168. WOODARD GA, Dacic S
     Should the TNM Staging of NSCLC Evolve Beyond Anatomical Descriptors?
     J Thorac Oncol. 2024;19:663-665.
     PubMed    
     
     
     
169. LUO J, Sanchez M, Lee E, Hertzler H, et al
     Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
     J Thorac Oncol. 2024;19:829-838.
     PubMed     Abstract available
     
     
     
170. OU SI, Hagopian GG, Zhang SS, Nagasaka M, et al
     Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central beta-Sheet 6 [Cbeta6] Mutation [L2086F]).
     J Thorac Oncol. 2024;19:706-718.
     PubMed     Abstract available
     
     
     April 2024
171. GADGEEL SM, Rodriguez-Abreu D, Halmos B, Garassino MC, et al
     Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
     J Thorac Oncol. 2024 Apr 18:S1556-0864(24)00169.
     PubMed     Abstract available
     
     
     
172. ERNST SM, van Marion R, Atmodimedjo PN, de Jonge E, et al
     Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib.
     J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165.
     PubMed     Abstract available
     
     
     
173. HORNE A, Harada K, Brown KD, Chua KLM, et al
     Treatment response biomarkers: working towards personalised radiotherapy for lung cancer.
     J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00164.
     PubMed     Abstract available
     
     
     
174. KIM IH, Lee GD, Choi S, Kim HR, et al
     Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer.
     J Thorac Oncol. 2024 Apr 11:S1556-0864(24)00160.
     PubMed     Abstract available
     
     
     
175. SHUKLA V, Wang H, Varticovski L, Baek S, et al
     Genome-wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in Small Cell Lung Cancer.
     J Thorac Oncol. 2024 Apr 5:S1556-0864(24)00131.
     PubMed     Abstract available
     
     
     
176. DETTERBECK FC, Ostrowski M, Hoffmann H, Rami-Porta R, et al
     The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9(th)) Edition of the TNM Classification of Lung Cancer.
     J Thorac Oncol. 2024 Apr 1:S1556-0864(24)00129.
     PubMed     Abstract available
     
     
     
177. CHANG CL, Lin KC, Chen WM, Shia BC, et al
     Correspondence: Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
     J Thorac Oncol. 2024;19:e2-e4.
     PubMed    
     
     
     
178. CHIOU CC, Lai TY
     Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Methodologic Issues.
     J Thorac Oncol. 2024;19:e1-e2.
     PubMed    
     
     
     
179. SMESSEIM I, Baas P
     Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From Australia.
     J Thorac Oncol. 2024;19:547-550.
     PubMed    
     
     
     
180. GRAY SG, Meirson T, Mutti L
     Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.
     J Thorac Oncol. 2024;19:541-546.
     PubMed    
     
     
     
181. SAIFO M, Alali M, Alhabeb H, Awak M, et al
     Lung Cancer in Syria.
     J Thorac Oncol. 2024;19:534-540.
     PubMed    
     
     
     
182. SHOENBILL KA, Goldstein AO
     Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening.
     J Thorac Oncol. 2024;19:531-533.
     PubMed    
     
     
     
183. ZHU Z, Chen H
     Additional Evidence for Postoperative Radiation Therapy on Thymic Carcinoma.
     J Thorac Oncol. 2024;19:528-530.
     PubMed    
     
     
     
184. LEE JB, Nagasaka M
     Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?
     J Thorac Oncol. 2024;19:525-527.
     PubMed    
     
     
     
185. LEONG TL, McWilliams A, Wright GM
     Incidental Pulmonary Nodules: An Opportunity to Complement Lung Cancer Screening.
     J Thorac Oncol. 2024;19:522-524.
     PubMed    
     
     
     
186. DWYER LJ, Singhal N, Yu B, Kao S, et al
     Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report.
     J Thorac Oncol. 2024;19:650-652.
     PubMed     Abstract available
     
     
     
187. RIMNER A, Ahmad U, Lobaugh SM, Zhang Z, et al
     Postoperative Radiation Therapy for Thymic Carcinoma: An Analysis of the International Thymic Malignancy Interest Group/European Society of Thoracic Surgeons Database.
     J Thorac Oncol. 2024;19:626-635.
     PubMed     Abstract available
     
     
     
188. MCNAMEE N, Harvey C, Gray L, Khoo T, et al
     Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
     J Thorac Oncol. 2024;19:636-642.
     PubMed     Abstract available
     
     
     
189. NEL AE, Pavlisko EN, Roggli VL
     The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy.
     J Thorac Oncol. 2024;19:551-564.
     PubMed     Abstract available
     
     
     March 2024
190. TRAVIS WD, Eisele M, Nishimura KK, Aly R, et al
     The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carci
     J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122.
     PubMed     Abstract available
     
     
     
191. BORGEAUD M, Parikh K, Banna GL, Kim F, et al
     Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review.
     J Thorac Oncol. 2024 Mar 16:S1556-0864(24)00123.
     PubMed     Abstract available
     
     
     
192. HINES JB, Cameron RB, Esposito A, Kim L, et al
     Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.
     J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
     PubMed     Abstract available
     
     
     
193. CHENG Y, Fan Y, Zhao Y, Huang D, et al
     Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
     J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
     PubMed     Abstract available
     
     
     
194. RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
     The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
     PubMed     Abstract available
     
     
     
195. KIM BG, Yoon S, Lee SY, Sohn JW, et al
     How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
     J Thorac Oncol. 2024;19:509-510.
     PubMed    
     
     
     
196. WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
     Lung Cancer in Switzerland.
     J Thorac Oncol. 2024;19:385-394.
     PubMed    
     
     
     
197. TEN HAAF K
     Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
     J Thorac Oncol. 2024;19:373-375.
     PubMed    
     
     
     
198. LI CP, Tsai RY, Chang HC, Gau SY, et al
     Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
     J Thorac Oncol. 2024;19:507-508.
     PubMed    
     
     
     
199. CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
     Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
     J Thorac Oncol. 2024;19:380-384.
     PubMed    
     
     
     
200. LIM SM, Lee JB, Cho BC
     Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
     J Thorac Oncol. 2024;19:376-379.
     PubMed    
     
     
     
201. YALAMANCHALI A, Hassan KA
     MUC1-C: The Occam Razor of Osimertinib Resistance?
     J Thorac Oncol. 2024;19:370-372.
     PubMed    
     
     
     
202. DAMMEIJER F, Dumoulin DW, Aerts JGJV
     Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
     J Thorac Oncol. 2024;19:366-369.
     PubMed    
     
     
     
203. CANI M, Novello S, Bironzo P
     Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on Pie Slices.
     J Thorac Oncol. 2024;19:363-365.
     PubMed    
     
     
     
204. BORCZUK AC
     Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.
     J Thorac Oncol. 2024;19:360-362.
     PubMed    
     
     
     
205. YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
     Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation.
     J Thorac Oncol. 2024;19:409-424.
     PubMed     Abstract available
     
     
     February 2024
206. FONG KM, Rosenthal A, Giroux DJ, Nishimura KK, et al
     The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer.
     J Thorac Oncol. 2024 Feb 4:S1556-0864(24)00060.
     PubMed     Abstract available
     
     
     
207. ZHOU RX, Liao HJ, Hu JJ, Xiong H, et al
     Global burden of lung cancer attributable to household fine particulate matter pollution in 204 countries and territories, 1990-2019.
     J Thorac Oncol. 2024 Feb 2:S1556-0864(24)00034.
     PubMed     Abstract available
     
     
     
208. TORASAWA M, Horinouchi H
     A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
     J Thorac Oncol. 2024;19:351-352.
     PubMed    
     
     
     
209. NISHIMURA T
     A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment.
     J Thorac Oncol. 2024;19:350.
     PubMed    
     
     
     
210. HORITA N, Takase-Minegishi K
     Information Bias Might Exaggerate Lung Cancer Risk of Patients With Rheumatoid Arthritis.
     J Thorac Oncol. 2024;19:348.
     PubMed    
     
     
     
211. CHANG HC, Gau SY
     Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer.
     J Thorac Oncol. 2024;19:346.
     PubMed    
     
     
     
212. YUAN C, Huang R, Wang Y
     An Error in Modeling and the Selection of Independent Radiomics Variables Need Caution.
     J Thorac Oncol. 2024;19:344-345.
     PubMed    
     
     
     
213. BERMAS BL, Gerber DE
     The Joint Problem of Rheumatoid Arthritis and Lung Cancer.
     J Thorac Oncol. 2024;19:196-198.
     PubMed    
     
     
     
214. VOKES EE, Mornex F, Sezer A, Cheng Y, et al
     Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
     J Thorac Oncol. 2024;19:285-296.
     PubMed     Abstract available
     
     
     
215. REMON J, Saw SPL, Cortiula F, Singh PK, et al
     Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges.
     J Thorac Oncol. 2024;19:199-215.
     PubMed     Abstract available
     
     
     
216. DACIC S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, et al
     Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment.
     J Thorac Oncol. 2024;19:273-284.
     PubMed     Abstract available
     
     
     
217. OWONIKOKO TK
     SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
     J Thorac Oncol. 2024;19:193-195.
     PubMed    
     
     
     
218. LE X
     Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC.
     J Thorac Oncol. 2024;19:190-192.
     PubMed    
     
     
     
219. LEE JH
     Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
     J Thorac Oncol. 2024;19:187-189.
     PubMed    
     
     
     
220. SHIRAISHI Y, Tokito T, Toyozawa R, Inagaki C, et al
     Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
     J Thorac Oncol. 2024;19:337-343.
     PubMed     Abstract available
     
     
     January 2024
221. SHI Y, Hu X, Li X, Gong C, et al
     Ficonalkib (SY-3505) in Advanced ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Open-Label, Single-Arm, Phase I/? Study.
     J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035.
     PubMed     Abstract available
     
     
     
222. SHI Y, Chen J, Yang R, Wu H, et al
     Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive non-small cell lung cancer: interim analysis of a randomized, open-label, phase III study (INSPIRE).
     J Thorac Oncol. 2024 Jan 25:S1556-0864(24)00033.
     PubMed     Abstract available
     
     
     
223. NASSAR AH, Kim SY, Aredo JV, Feng J, et al
     Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
     J Thorac Oncol. 2024 Jan 24:S1556-0864(24)00032.
     PubMed     Abstract available
     
     
     
224. SIMONS E, Camidge DR
     Lung cancer oncogene-directed therapy, fertility and pregnancy.
     J Thorac Oncol. 2024 Jan 5:S1556-0864(24)00023.
     PubMed     Abstract available
     
     
     
225. YU S, Feng J
     Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".
     J Thorac Oncol. 2024;19:173-174.
     PubMed    
     
     
     
226. TANIZAKI J, Hayashi H
     Unraveling Pseudo Kidney Injury: The Significance of Understanding Our "MATE" in Molecular-Targeted Therapies.
     J Thorac Oncol. 2024;19:15-17.
     PubMed    
     
     
     
227. BATAH H, Majeed Z, Moudgil R
     Tale of Two Cs: Inter-Relationship Between Cardiovascular and Lung Cancer.
     J Thorac Oncol. 2024;19:13-14.
     PubMed    
     
     
     
228. SINGHAL S, Gandara D, Riess JW
     Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape.
     J Thorac Oncol. 2024;19:10-12.
     PubMed    
     
     
     
229. FANG W, Girard N, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2024;19:52-70.
     PubMed     Abstract available
     
     
     
230. CHEN MF, Harada G, Liu D, DeMatteo R, et al
     Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
     J Thorac Oncol. 2024;19:153-159.
     PubMed     Abstract available
     
     
     
231. UDAGAWA H, Nilsson MB, Robichaux JP, He J, et al
     HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
     J Thorac Oncol. 2024;19:106-118.
     PubMed     Abstract available
     
     
     
232. HAMADA A, Suda K, Nishino M, Obata K, et al
     Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
     J Thorac Oncol. 2024;19:71-79.
     PubMed     Abstract available
     
     
     
233. LAM S, Wynes MW, Connolly C, Ashizawa K, et al
     The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative.
     J Thorac Oncol. 2024;19:94-105.
     PubMed     Abstract available
     
     
     
234. TAGLIAMENTO M, Di Maio M, Remon J, Bironzo P, et al
     Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
     J Thorac Oncol. 2024;19:166-172.
     PubMed     Abstract available
     
     
     December 2023
235. YANG JC, Han B, De La Mora Jimenez E, Lee JS, et al
     Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non?Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/=1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
     J Thorac Oncol. 2023 Dec 28:S1556-0864(23)02432.
     PubMed     Abstract available
     
     
     
236. ODINTSOV I, Makarem M, Nishino M, Bachert SE, et al
     Prevalence and Therapeutic Targeting of High Level ERBB2 Amplification in Non-Small Cell Lung Cancer.
     J Thorac Oncol. 2023 Dec 26:S1556-0864(23)02428.
     PubMed     Abstract available
     
     
     
237. BISCHOFF P, Reck M, Overbeck T, Christopoulos P, et al
     Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).
     J Thorac Oncol. 2023 Dec 12:S1556-0864(23)02423.
     PubMed     Abstract available
     
     
     
238. VAN SCHIL PE, Asamura H, Nishimura KK, Rami-Porta R, et al
     The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02411.
     PubMed     Abstract available
     
     
     
239. LI W, Fei K, Guo L, Wang Y, et al
     CD74/SLC34A2-ROS1 fusion variants involving the transmembrane region predict poor response to crizotinib in non-small cell lung cancer independent of TP53 mutations.
     J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02414.
     PubMed     Abstract available
     
     
     
240. DACIC S, Travis WD, Giltnane JM, Kos F, et al
     Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
     J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415.
     PubMed     Abstract available
     
     
     
241. XHEMALAJ D, Gradica F, Skenduli I, Tula J, et al
     Lung Cancer in Albania.
     J Thorac Oncol. 2023;18:1632-1637.
     PubMed    
     
     
     
242. FERREIRA M, Redman MW, Reckamp KL
     Moving Toward Rationale Phase 3 Designs for Advanced NSCLC.
     J Thorac Oncol. 2023;18:1629-1631.
     PubMed    
     
     
     
243. LI Z, Lu S
     Third-Generation EGFR Tyrosine Kinase Inhibitor for Central Nervous System Metastases EGFR-Mutant NSCLC: Current Evidence and Future Perspectives.
     J Thorac Oncol. 2023;18:1625-1628.
     PubMed    
     
     
     
244. MAKAREM M, Rotow JK
     Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response.
     J Thorac Oncol. 2023;18:1615-1617.
     PubMed    
     
     
     
245. RUFFINI E, Huang J, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2023;18:1655-1671.
     PubMed     Abstract available
     
     
     
246. MAROM EM, Fang W, Ruffini E, Detterbeck F, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic
     J Thorac Oncol. 2023;18:1672-1688.
     PubMed     Abstract available
     
     
     
247. OKUMURA M, Marino M, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2023;18:1638-1654.
     PubMed     Abstract available
     
     
     
248. ANG YLE, Soo RA
     Has the Ship Sailed on Second-Generation ALK Tyrosine Kinase Inhibitors in the Post-Crizotinib Setting?
     J Thorac Oncol. 2023;18:1621-1624.
     PubMed    
     
     
     
249. MEDINA CG, Xu Y, Ripley RT
     International Prognostic Modeling: A Platform for Collaborative Approach for Patients With Mesothelioma.
     J Thorac Oncol. 2023;18:1618-1620.
     PubMed    
     
     
     
250. SOO RA, Cho BC, Kim JH, Ahn MJ, et al
     Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
     J Thorac Oncol. 2023;18:1756-1766.
     PubMed     Abstract available
     
     
     
251. WOLF AS, Rosenthal A, Giroux DJ, Nowak AK, et al
     The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma.
     J Thorac Oncol. 2023;18:1689-1702.
     PubMed     Abstract available
     
     
     November 2023
252. WANG K, Du R, Myall NJ, Lewis WE, et al
     BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).
     J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02376.
     PubMed     Abstract available
     
     
     
253. O'LEARY CL, Pierce N, Patel SP, Naidoo J, et al
     Immune-Related Toxicity in Non-small cell Lung Cancer: Current State-of-The-Art and Emerging Clinical Challenges.
     J Thorac Oncol. 2023 Nov 25:S1556-0864(23)02374.
     PubMed     Abstract available
     
     
     
254. LIAO W, Fehnel C, Goss J, Shepherd CJ, et al
     Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening in a Mississippi Delta Cohort.
     J Thorac Oncol. 2023 Nov 18:S1556-0864(23)02371.
     PubMed     Abstract available
     
     
     
255. LU C, Wei XW, Wang Z, Zhou Z, et al
     Allelic context of EGFR C797X mutant lung cancer defines four subtypes with heterogeneous genomic landscape and distinct clinical outcomes.
     J Thorac Oncol. 2023 Nov 17:S1556-0864(23)02372.
     PubMed     Abstract available
     
     
     
256. HENSCHKE C, Huber R, Jiang L, Yang D, et al
     Perspective on Management of LDCT Findings on Low-Dose Computed Tomography Examinations for Lung Cancer Screening From the IASLC Early Detection & Screening Committee.
     J Thorac Oncol. 2023 Nov 16:S1556-0864(23)02369.
     PubMed     Abstract available
     
     
     
257. GULATI S, Ivic-Pavlicic T, Joasil J, Flores R, et al
     Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.
     J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02364.
     PubMed     Abstract available
     
     
     
258. CARTMEL B, Fucito LM, Bold KW, Neveu S, et al
     No Additional Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening: Brief Report of a Randomized Trial.
     J Thorac Oncol. 2023 Nov 15:S1556-0864(23)02368.
     PubMed     Abstract available
     
     
     
259. YANG JJ, Wen W, Zahed H, Zheng W, et al
     Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
     J Thorac Oncol. 2023 Nov 7:S1556-0864(23)02352.
     PubMed     Abstract available
     
     
     
260. KUBO N, Suefuji H, Nakajima M, Tokumaru S, et al
     Five-year survival outcomes after carbon-ion radiotherapy for operable stage I non-small cell lung cancer: a Japanese national registry study (J-CROS-LUNG).
     J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02346.
     PubMed     Abstract available
     
     
     
261. HARATAKE N, Ozawa H, Morimoto Y, Yamashita N, et al
     MUC1-C IS A COMMON DRIVER OF ACQUIRED OSIMERTINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER.
     J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02348.
     PubMed     Abstract available
     
     
     
262. HONG TH, Hwang S, Cho J, Choi YL, et al
     Clinical Significance of the Proposed Pathologic Criteria for Invasion by the International Association for the Study of Lung Cancer in Resected Nonmucinous Lung Adenocarcinoma.
     J Thorac Oncol. 2023 Nov 2:S1556-0864(23)02311.
     PubMed     Abstract available
     
     
     
263. QIU Z, Huang H, Zhang Y, Chen D, et al
     Comment on "Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report".
     J Thorac Oncol. 2023;18:e138-e139.
     PubMed    
     
     
     
264. LI A, Yang Y, Zhang L, Hong S, et al
     STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes.
     J Thorac Oncol. 2023;18:e135-e138.
     PubMed    
     
     
     
265. AMORI G, Sugawara E, Inamura K
     Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
     J Thorac Oncol. 2023;18:e134-e135.
     PubMed    
     
     
     
266. CHEN WM, Yu YH, Chen M, Shia BC, et al
     Correspondence: The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
     J Thorac Oncol. 2023;18:e132-e134.
     PubMed    
     
     
     
267. ZHANG Y, Dai K, He D, Chen Z, et al
     The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.
     J Thorac Oncol. 2023;18:e130-e131.
     PubMed    
     
     
     
268. NIU Y, Yao F, Yang H
     "Keaping" an Eye on the NRF2 Signature Score: Expanding Its Applicability in Lung Cancer.
     J Thorac Oncol. 2023;18:e126-e128.
     PubMed    
     
     
     
269. MARTI JLG, Wells JZ, Wells A
     Statins as a Secondary Preventive Agent for Metastatic Cancer.
     J Thorac Oncol. 2023;18:e125-e126.
     PubMed    
     
     
     
270. OKONTA KE, Baiyewu LA, Jimoh MA
     Lung Cancer in Nigeria.
     J Thorac Oncol. 2023;18:1446-1457.
     PubMed    
     
     
     
271. DAGOGO-JACK I
     We Don't Talk (Enough) About BRAF.
     J Thorac Oncol. 2023;18:1443-1445.
     PubMed    
     
     
     
272. LEE JB, Ou SI
     Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?
     J Thorac Oncol. 2023;18:1434-1442.
     PubMed    
     
     
     
273. HIJAZO-PECHERO S, Munoz-Pinedo C, Nadal E
     A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
     J Thorac Oncol. 2023;18:1431-1433.
     PubMed    
     
     
     
274. SOZZI G, Pastorino U
     Small RNAs Do It Better.
     J Thorac Oncol. 2023;18:1428-1430.
     PubMed    
     
     
     
275. YANKELEVITZ DF, Yip R, Henschke CI
     Considerations for Incorporating Family History Into Low-dose Computed Tomography Screening Recommendations.
     J Thorac Oncol. 2023;18:1426-1427.
     PubMed    
     
     
     
276. SAKAI T, Matsumoto S, Ueda Y, Shibata Y, et al
     Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).
     J Thorac Oncol. 2023;18:1538-1549.
     PubMed     Abstract available
     
     
     
277. AHN MJ, Bondarenko I, Kalinka E, Cho BC, et al
     Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
     J Thorac Oncol. 2023;18:1594-1606.
     PubMed     Abstract available
     
     
     October 2023
278. WANG L, Luo Y, Ren S, Zhang Z, et al
     A phase Ib study of ivonescimab, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy naive non-small-cell lung cancer.
     J Thorac Oncol. 2023 Oct 23:S1556-0864(23)02312.
     PubMed     Abstract available
     
     
     
279. HUANG J, Osarogiagbon RU, Giroux DJ, Nishimura KK, et al
     The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 9th Edition of the TNM Classification for Lung Cancer.
     J Thorac Oncol. 2023 Oct 20:S1556-0864(23)02310.
     PubMed     Abstract available
     
     
     
280. CHO MH, Cho JH, Eun Y, Han K, et al
     Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study.
     J Thorac Oncol. 2023 Oct 12:S1556-0864(23)02293.
     PubMed     Abstract available
     
     
     
281. STOCKHAMMER P, Grant M, Wurtz A, Foggetti G, et al
     Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer.
     J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02264.
     PubMed     Abstract available
     
     
     
282. HENSCHKE CI, Yip R, Sun Q, Li P, et al
     Prospective Cohort Study to Compare Long-term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a-b;
     J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02265.
     PubMed     Abstract available
     
     
     
283. ROTOW JK, Lee JK, Madison RW, Oxnard GR, et al
     Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms, and clinical landscape of non-small cell lung cancer (NSCLC) post-osimertinib.
     J Thorac Oncol. 2023 Oct 6:S1556-0864(23)02263.
     PubMed     Abstract available
     
     
     
284. TRIPHURIDET N, Gao Y, Ou SI
     Reply to Jayaraj et al. "Clinical Validity and Conceptual Interpretation of the Meta-Analysis on the Efficacy of LDCT Lung Cancer Screening in Never-Smokers".
     J Thorac Oncol. 2023;18:e122-e123.
     PubMed    
     
     
     
285. JAYARAJ R, Shetty S, Ilankumaran S, Merchant Y, et al
     Clinical Validity and Conceptual Interpretation of Low-Dose Computed Tomography Screening in Asian Female Never-Smokers Are as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers.
     J Thorac Oncol. 2023;18:e118-e122.
     PubMed    
     
     
     
286. CHOUR A, Duruisseaux M
     Response to Commentary on "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-PD(L)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer".
     J Thorac Oncol. 2023;18:e114-e115.
     PubMed    
     
     
     
287. DETTERBECK FC, Asamura H, Rami-Porta R, Rusch VW, et al
     The Only Constant Is Change: Introducing the International Association for the Study of Lung Cancer Proposals for the Ninth Edition of TNM Stage Classification of Thoracic Tumors.
     J Thorac Oncol. 2023;18:1258-1260.
     PubMed    
     
     
     
288. INAMURA K
     Exploiting Tumor Immune Microenvironment to Predict Response to Immunotherapy Plus Chemotherapy in NSCLC.
     J Thorac Oncol. 2023;18:e109-e110.
     PubMed    
     
     
     
289. ADJEI AA
     The Coming of a New Age: The Journal of Thoracic Oncology Goes Electronic in 2024.
     J Thorac Oncol. 2023;18:1257.
     PubMed    
     
     
     
290. HOE HJ, Balasubramanian A, John T
     LASERing FLAURAL Arrangements in Asian EGFR Subsets.
     J Thorac Oncol. 2023;18:1261-1264.
     PubMed    
     
     
     
291. REUNGWETWATTANA T, Cho BC, Lee KH, Pang YK, et al
     Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
     J Thorac Oncol. 2023;18:1351-1361.
     PubMed     Abstract available
     
     
     
292. PEARSALL SM, Williamson SC, Humphrey S, Hughes E, et al
     Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.
     J Thorac Oncol. 2023;18:1362-1385.
     PubMed     Abstract available
     
     
     
293. GELSOMINO F, Vitale G, Raschi E, Ardizzoni A, et al
     Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical Issue.
     J Thorac Oncol. 2023;18:e112-e113.
     PubMed    
     
     
     
294. CHEN WM, Yu YH, Chen M, Shia BC, et al
     Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma.
     J Thorac Oncol. 2023;18:e107-e109.
     PubMed    
     
     
     
295. LIN TA, Chen SY, Chang R, Sun CK, et al
     Correspondence: Statin Use During Concurrent Chemoradiotherapy With Improved Survival Outcomes in Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Nationwide Cohort Study.
     J Thorac Oncol. 2023;18:e105-e106.
     PubMed    
     
     
     
296. WRIGHT K, Digby GC, Gyawali B, Jad R, et al
     Malignant Superior Vena Cava Syndrome: A Scoping Review.
     J Thorac Oncol. 2023;18:1268-1276.
     PubMed     Abstract available
     
     
     September 2023
297. DUAN J, Wu L, Yang K, Zhao J, et al
     Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations: A phase I trial.
     J Thorac Oncol. 2023 Sep 28:S1556-0864(23)02259.
     PubMed     Abstract available
     
     
     
298. RECK M, Barlesi F, Chih-Hsin Yang J, Westeel V, et al
     Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.
     J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02250.
     PubMed     Abstract available
     
     
     
299. JIANG C, Zhang Y, Fu F, Deng P, et al
     A Shift in Paradigm: Selective Lymph Node Dissection for Minimizing Oversurgery in Early-Stage Lung Cancer.
     J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02245.
     PubMed     Abstract available
     
     
     
300. TORASAWA M, Horinouchi H, Nomura S, Igawa S, et al
     Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
     J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02256.
     PubMed     Abstract available
     
     
     
301. WANG X, Bai H, Zhang J, Wang Z, et al
     Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.
     J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01079.
     PubMed     Abstract available
     
     
     
302. FIGUEROA PU, Marques E, Cilento VJ, Giroux DJ, et al
     Completeness of Resection and Long-term Survival of Patients Undergoing Resection for Pathological T3 Non-small-cell Lung Cancer: An International Association for the Study of Lung Cancer Analysis.
     J Thorac Oncol. 2023 Sep 15:S1556-0864(23)01078.
     PubMed     Abstract available
     
     
     
303. ZHANG S, Liu L, Shi S, He H, et al
     Bidirectional association between cardiovascular disease and lung cancer in a prospective cohort study.
     J Thorac Oncol. 2023 Sep 11:S1556-0864(23)00806.
     PubMed     Abstract available
     
     
     August 2023
304. DACIC S, Travis W, Redman M, Saqi A, et al
     International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
     J Thorac Oncol. 2023 Aug 3:S1556-0864(23)00685.
     PubMed     Abstract available
     
     
     
305. LIN SH
     Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?
     J Thorac Oncol. 2023;18:970-971.
     PubMed    
     
     
     July 2023
306. RIMNER A, Ruffini E, Cilento V, Goren E, et al
     The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors.
     J Thorac Oncol. 2023 Jul 24:S1556-0864(23)00672.
     PubMed     Abstract available
     
     
     June 2023
307. PIETROLUONGO E, De Placido P, Tortora M, Martinelli C, et al
     Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors.
     J Thorac Oncol. 2023 Jun 28:S1556-0864(23)00634.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.